Tue, December 2, 2008
Mon, December 1, 2008
Sun, November 30, 2008
Fri, November 28, 2008
Thu, November 27, 2008
Wed, November 26, 2008
Tue, November 25, 2008
[ Tue, Nov 25th 2008 ] - Market Wire
HST Global Quarterly Update
Mon, November 24, 2008
Thu, November 20, 2008
Wed, November 19, 2008
Tue, November 18, 2008
Mon, November 17, 2008

Webcast Alert: Lpath Third Quarter Business Review Teleconference


//health-fitness.news-articles.net/content/2008/ .. hird-quarter-business-review-teleconference.html
Published in Health and Fitness on Monday, November 17th 2008 at 8:15 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Lpath Inc. (OTCBB: LPTN) announces the following Webcast:

What: Third Quarter Business Review Teleconference

When: November 19, 2008 @ 11:00 AM Eastern

Where: [ http://www.investorcalendar.com/ClientPage.asp?ID=137931 ]

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Deirdre Abbotts, (203) 222-7399 x10, [ dabbotts@redingtoninc.com ]

If you are unable to participate during the live webcast, the call will be available for replay at [ http://www.investorcalendar.com/ClientPage.asp?ID=137931 ] or [ http://www.investorcalendar.com/ ]

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutics that targets bioactive signaling lipids to treat human diseases. The company's lead product includes ASONEP, which is in Phase I clinical trials, is a humanized monoclonal antibody against sphingosine-1-phosphate for the treatment of cancer and multiple sclerosis, as well as other angiogenic-related diseases and inflammatory-oriented indications. Its products also comprise iSONEP, the ocular formulation of Sonepcizumab for the treatment of age-related macular degeneration, retinopathy, and glaucoma; and Lpathomab, a monoclonal antibody against lysophosphatidic acid for the treatment of Cancer, fibrosis and neuropathic pain, and fibrotic ocular diseases. The company was founded in 1997 and is based in San Diego, California.


Publication Contributing Sources